Follow Illumina to never miss an important update.
Illumina reported earnings of $1.62 per share, well above the $1.36 analysts were expecting. Revenue reached $1.17 billion, also topping estimates, as the company saw healthy demand for its genetic sequencing machines and the chemical kits used to run them. Management noted that placements of its newest high-end platform, the NovaSeq X, are ahead of schedule.
Following the strong quarter, the company raised its financial targets for the full year. This is a positive sign for the business as it refocuses on its core sequencing technology after spinning off its cancer-testing unit, GRAIL. The growth in clinical demand suggests that genetic testing is becoming more routine in healthcare, which helps protect Illumina's long-term revenue.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Illumina launched BioInsight, a new software environment designed to handle the massive amounts of data produced by its sequencing machines. The platform uses artificial intelligence to help scientists identify biological patterns more quickly, which is a key part of making genetic research more efficient.
This move is important because it strengthens Illumina's "razor and blade" business model. By providing better software to analyze the data, Illumina makes its hardware more useful and keeps customers locked into its ecosystem. It also includes an update to its DRAGEN analysis tool, which helps labs process data more accurately.
Source: PRNewsWire
Illumina introduced SpliceAI2, an updated artificial intelligence tool designed to help researchers understand how genetic changes affect the body. In early tests, the model identified 17 percent more variants related to rare diseases compared to older methods. While this is a specialized tool, it helps maintain Illumina's position as the primary technology provider for genetic research labs.
Source: PRNewsWire
On October 8, Illumina entered into agreements to create a commercial paper program, which allows it to issue short-term, unsecured debt. The company can have up to $1 billion in these notes outstanding at any time, with the money intended for general corporate purposes. This is a routine financial move that gives the company more flexibility to manage its daily cash needs and expenses.
Source: 8-K filing
Canaccord Genuity raised its price target for Illumina to $300 from $205 but kept its rating at Hold. This means the firm thinks the stock is fairly valued at its current price rather than being a clear buy. The new target is slightly above the current average of $253 across all analysts who follow the company.
Source: Canaccord Genuity
Management has a consistent habit of setting targets they can clear, delivering seven beats in the last eight quarters. This pattern suggests they have a firm handle on their costs and the timing of new machine sales.
| Expectation | |
|---|---|
| EPS | $1.36 |
| Revenue | $1.15B |